A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia

Completed · Phase 2 · Has a placebo group

Conditions studied: Congenital Adrenal Hyperplasia

In brief

This is a Phase 2 multicenter, single-blind, multiple dose study to evaluate the safety and efficacy of orally administered ATR-101 in subjects with classic congenital adrenal hyperplasia (CAH). Treatment duration will range from a minimum of approximately 2 months to 6 months per subject. A subject may receive a minimum of one dose level or up to a maximum of 5 dose levels, in sequentially increasing dose strengths. Each dose level will last 28 days.

Key facts

Study ID
NCT02804178
Run by
Millendo Therapeutics, Inc.
People needed
10
Starts
2016-05-18
Expected to finish
2017-08-17
Last updated by the study team
2021-03-10

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.